Masaru Matsuda Sells 40,638 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 40,638 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.28, for a total value of $1,027,328.64. Following the transaction, the insider directly owned 110,003 shares of the company’s stock, valued at approximately $2,780,875.84. The trade was a 26.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Masaru Matsuda also recently made the following trade(s):

• On Monday, December 1st, Masaru Matsuda sold 1,657 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $30.23, for a total transaction of $50,091.11.
• On Wednesday, November 19th, Masaru Matsuda sold 2,550 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $28.29, for a total transaction of $72,139.50.

Arcutis Biotherapeutics Price Performance

ARQT traded down $0.11 during midday trading on Wednesday, hitting $26.08. 2,300,007 shares of the company traded hands, compared to its average volume of 1,375,938. The business has a 50 day simple moving average of $28.23 and a two-hundred day simple moving average of $22.43. Arcutis Biotherapeutics, Inc. has a 52-week low of $11.13 and a 52-week high of $31.77. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -72.44 and a beta of 1.70. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68.

Institutional Trading of Arcutis Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Johnson Investment Counsel Inc. acquired a new stake in shares of Arcutis Biotherapeutics during the 3rd quarter worth approximately $30,000. SBI Securities Co. Ltd. grew its position in Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after acquiring an additional 833 shares during the period. PNC Financial Services Group Inc. increased its stake in Arcutis Biotherapeutics by 10.2% during the second quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock worth $124,000 after acquiring an additional 820 shares during the last quarter. Jones Financial Companies Lllp raised its position in Arcutis Biotherapeutics by 1,291.1% in the third quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock valued at $124,000 after purchasing an additional 6,559 shares during the period. Finally, Atlas Wealth LLC purchased a new stake in Arcutis Biotherapeutics in the second quarter valued at $138,000.

Analyst Ratings Changes

A number of equities analysts have commented on the company. The Goldman Sachs Group increased their target price on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Needham & Company LLC increased their price objective on Arcutis Biotherapeutics from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 26th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Arcutis Biotherapeutics in a report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Finally, Zacks Research downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $29.20.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Neutral Sentiment: Short-interest report shows effectively 0 shares short as of Feb. 3 — the data appears anomalous (increase listed as NaN and a 0.0-day days-to-cover). This reading is unlikely to be meaningful for near-term price direction.
• Negative Sentiment: Multiple insider sales totaling roughly 46,700 shares and ~ $1.19M in proceeds were disclosed (early Feb). While insiders still hold large positions, the coordinated sales by senior executives and a director increase selling pressure and may amplify negative sentiment:
  • Larry Todd Edwards sold 2,052 shares at ~$25.50 (≈ $52,326). Larry Todd Edwards Form 4
  • Director Howard G. Welgus sold 10,000 shares at ~$25.05 (≈ $250,500). Howard Welgus Form 4
  • CFO Latha Vairavan sold 1,320 shares at ~$25.50 (≈ $33,660). Latha Vairavan Form 4
  • Todd Watanabe sold 19,833 shares at ~$25.50 (≈ $505,742). Todd Watanabe Form 4
  • Patrick Burnett reported two sales (3,675 shares at $25.50 and 9,794 shares at $25.81; combined ≈ $346,496). Patrick Burnett Form 4

  About Arcutis Biotherapeutics

  Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

  In August 2022, Arcutis received U.S.

  Featured Articles

  • Five stocks we like better than Arcutis Biotherapeutics
  • [No Brainer Gold Play]: “Show me a better investment.”
  • The gold chart Wall Street is terrified of…
  • NEW LAW: Congress Approves Setup For Digital Dollar?
  • GOLD ALERT
  • What a Former CIA Agent Knows About the Coming Collapse